Vertex’s Non-CF Revenue Surpasses $500M — But Can It Keep Scaling?

Date of Call: Feb 12, 2026

Financials Results

• Revenue: Q4: $3.2B, up 10% YOY; Full Year: $12B, up 9% YOY
• EPS: Q4: $5.03 per share, up 26% YOY; Full Year: $18.40 per share
• Gross Margin: Q4: 85.7%; a reasonable proxy for 2026

Guidance:

• Full year 2026 total revenue expected to be $12.95B to $13.1B, representing 8% to 9% growth YOY.
• Non-CF products expected to contribute $500M or more.
• Q1 2026 total revenue growth anticipated to be approximately 7% YOY, accelerating thereafter.
• Combined non-GAAP operating expenses expected to be $5.65B to $5.75B.
• Non-GAAP effective tax rate anticipated to be 19.5% to 20.5%.

Business Commentary:

Revenue Growth and Diversification:

• Vertex Pharmaceuticals reported a 10% increase in total revenue for Q4 2025, reaching $3.2 billion, and a 9% increase for the full year 2025, reaching $12 billion.
• The growth was driven by disciplined commercial execution in cystic fibrosis (CF) and successful new product launches, including CASGEVY and JOURNAVX.

Cystic Fibrosis Therapies:

• Vertex's CF therapies contributed to 7% global revenue growth in 2025, with the U.S. market growing 11% year-over-year.
• This was due to pediatric uptake, strong performance of TRIKAFTA and ALYFTREK, higher realized net prices, and new reimbursement agreements.

Expansion of Product Portfolio:

• The company achieved $116 million in CASGEVY revenue and $60 million in JOURNAVX revenue in 2025, contributing to non-CF product revenue of $500 million or more in the guidance for 2026.
• This growth is attributed to building momentum in patient initiations and first cell collections for CASGEVY and strong prescription growth for JOURNAVX.

Renal Franchise Development:

• Vertex is advancing its renal pipeline with povetacicept, targeting IgA nephropathy (IgAN) and membranous nephropathy, with Breakthrough Therapy designation and Rolling Review from the FDA.
• The focus on underlying disease mechanisms and engineered protein format are key drivers for potential best-in-class profile in these renal indications.

Strategic Commercial Execution:

• JOURNAVX achieved over 550,000 prescriptions in 2025, with a balanced split between hospital and retail channels, and secured access for over 200 million lives.
• This success is due to strategic partnerships with PBMs, integration into hospital formularies, and a broad prescriber base across multiple specialties.

Sentiment Analysis:

Overall Tone: Positive

• Management described 2025 as marked by 'excellent progress' and 'robust financial performance.' They noted 'strong quarter 4 '25 results' and 'continued momentum' for key products. The tone was optimistic regarding pipeline progress, stating 'we are entering an exciting period' and 'Vertex is well positioned to deliver on the significant opportunities.'

Q&A:

• Question from Cory Kasimov (Evercore ISI): Curious how you view the risk of potential hypogamma adverse events and how this could ultimately impact the label, if at all?
  Response: Management cited clinical data showing no serious infections or severe infections associated with low IgG levels; overall benefit-risk profile is viewed as very good.

• Question from Salveen Richter (Goldman Sachs): With regard to the guidance here, is there any way you could help us understand what's baked into the guide for the CF component relative to ALYFTREK and TRIKAFTA? And on ALYFTREK in particular, you had a strong quarter. So walk us through the contributing factors here as we think of the trajectory for 2026.
  Response: CFO declined to break down CF contribution within guidance; Chief Commercial Officer attributed strong ALYFTREK results to international launch and reimbursement wins in Europe, which will continue into 2026.

• Question from Geoffrey Meacham (Citigroup): Is there work to do on the payer side when you think about access and reimbursement and maybe cost benefit? And then just a follow-up on ALY. Is there more interest in the U.S. in using sweat chloride as a disease biomarker? And you mentioned the European launch. I mean, how would you characterize maybe the awareness and willingness to switch to ALY compared to the U.S.
  Response: On ALY, physician interest in sweat chloride is similar between U.S. and Europe; willingness to switch is influenced by fewer monitoring requirements in Europe and rapid uptake in treatment-naive patients. On pove, payer engagements are going extremely well, with 74 engagements covering over 210 million lives, and conversations are very positive.

• Question from Tazeen Ahmad (BofA Securities): With relation to pove, can we talk about what you're expecting to show on proteinuria? Like what results do you think would provide, in your mind, medically clinically differentiated data versus competitors?
  Response: Cited the RUBY-3 Phase II result of a 56% reduction in proteinuria as the best analog; emphasized the importance of deeper proteinuria reduction for long-term renal outcomes, which would be very meaningful clinically.

• Question from Evan Seigerman (BMO Capital Markets): I'd love for you to expand on the rationale to study pove in gMG. Just seems to be a more crowded rare disease. I'd love for you to just touch on what differentiates this asset, what you saw potentially kind of in earlier studies and how you think it would compare to both assets that have been approved and are under investigation for the indication.
  Response: Highlighted gMG as a sizable B-cell-mediated disease with treatment limitations, including the need to cycle off medications. Expressed excitement about pove's engineered fusion protein design, which may offer improved potency and efficacy over existing assets, based on cross-study comparisons with wild-type TACI.

• Question from Michael Yee (UBS): First, on pove, can you remind us how to think about what rates of ADA are possible, either absolute rates or neutralizing rates? And do you expect that to be of any material number given it's a chronic drug that could be something to think about? And then I don't think anyone's asked on AMKD, but obviously, you have a very potent drug there, and that data could be in about a year or so. And just wanted to think about how you expect those results to play out. And given you have a more heterogeneous population rather than just FSGS, do you expect essentially the same results from the Phase II?
  Response: On pove ADA, management stated that neutralizing antibodies would impact efficacy, but based on RUBY-3 data, it is not expected to be a material issue. On AMKD, expects Phase III results similar to Phase II, with the readout being GFR slope; data expected late 2025/early 2026.

• Question from Eliana Merle (Barclays): Just on JOURNAVX, how do you see the mix between retail and the hospital setting evolving over the course of the year? And how should we think about how that mix could impact gross to net as well as treatment duration?
  Response: Mix is expected to shift more toward retail; impact on gross-to-net depends on prescription duration, patient type, and insurance status, with various dynamics influencing the conversion.

• Question from William Pickering (Bernstein): If you could discuss how you expect the baseline GFR to impact the observed effect size, I think your Phase II patients had an average GFR about 10 mLs higher than the competitor Phase II or Phase III trials. And so if we were to see a Phase III baseline for pove, it's more similar to those competitor trials. Just wondering directionally, which way, if at all, that would influence effect size.
  Response: In the studied proteinuria range, baseline GFR is not expected to have a great impact on proteinuria response.

• Question from Brian Abrahams (RBC Capital Markets): I was just wondering if there are any differences such as proportion of patients from China or the degree of patients on SGLT2 inhibitors that might impact proteinuria response to povetacicept. And then also, is there any reason as we sort of think about a proxy for the potential magnitude of what we might see not to include the blend of UPCR reductions from both the 80 mg and 240 mg doses from RUBY-3 just to, I guess, get to a higher end. I'm just wondering if there's any reason 240 mg might have conferred lesser activity mechanistically.
  Response: The key difference between Phase II and III trials is the placebo arm; otherwise, criteria and doses are the same. 240 mg data showed activity similar to 80 mg.

• Question from Terence Flynn (Morgan Stanley): First one, unsurprisingly on Pove. I was wondering, Reshma, if you can comment at all about the blinded serious infection data you're seeing from the RAINIER study at this point? And then the second was on the WuXi deal. I know you mentioned you're developing this TCE for B cell-mediated autoimmune conditions. Just wondering how you think about differentiation there on the portfolio in terms of where you might carve out those indications relative to pove.
  Response: Blinded data reviewed by DSMB has resulted in clean bills of health with no changes requested. On WuXi, declined to share specifics but indicated trispecific engagers could complement the pove pipeline for various B-cell diseases.

• Question from Moritz Reiterer (Guggenheim): First, looking at the RUBY-3 UPCR data, pove had a much larger standard error than atacicept, sibeprenlimab in their comparable studies. Any comment on what may have caused this variability? And second, as atacicept and sibeprenlimab's Phase III studies showed very different placebo rates in their UPCR interim analysis. What's your assumption for the placebo rate in the RAINIER interim?
  Response: Attributed standard error variability to factors like sample size and lab test methods. Assumed placebo rate in RAINIER is 0% to 5% for proteinuria improvement.

• Question from Philip Nadeau (TD Cowen): We want to ask about the $500 million guidance for products outside of CF. First, could you give us some sense of the breakdown between CASGEVY and JOURNAVX in that number? And then second, that is a big increase, a 3-fold increase over 2025 and an approximate doubling versus the Q4 run rate. What gives you confidence in that level of growth? Is it CASGEVY infusions, CASGEVY self-harvest that are happening, visibility from payers on JOURNAVX? Can you give us some sense of what you're seeing to put that number out there?
  Response: Declined to break down the $500M+ non-CF contribution. Confidence stems from strong 2025 patient initiations for CASGEVY (over 300) providing visibility for 2026 ramp, and JOURNAVX prescriptions expected to triple in 2026 with greater revenue conversion due to improved access.

Contradiction Point 1

ALYFTREK Uptake Dynamics and Patient Switching

Contradiction on whether the majority of eligible patients have started ALYFTREK.

What are your key insights on the earnings performance? - Salveen Richter (Goldman Sachs)

2025Q4: The strong performance was driven by international reimbursement secured in Europe (UK, Germany, Denmark, Ireland, Norway) in 2025, which is expected to continue into 2026. - [Duncan J. McKechnie](CCO)

What's included in the 2026 guidance for the CF component (ALYFTREK and TRIKAFTA) and how should we interpret ALYFTREK's strong quarter? - Geoffrey Meacham (Citibank)

20251104-2025 Q3: The vast majority of newly eligible patients in the U.S. have started on ALYFTREK. Transition patients are switching steadily... - [Duncan J. McKechnie](CCO)

Contradiction Point 2

ALYFTREK Revenue Growth Guidance and Drivers

Contradiction on the specific confidence drivers for ALYFTREK's growth in the guidance.

What are the key drivers of your recent financial performance? - Salveen Richter (Goldman Sachs)

2025Q4: For ALYFTREK, the strong performance was driven by international reimbursement secured in Europe... which is expected to continue into 2026. - [Duncan J. McKechnie](CCO)

What details are included in the 2026 guidance for the CF component (ALYFTREK and TRIKAFTA), and how would you comment on ALYFTREK's strong quarterly performance? - Geoffrey Meacham (Citibank)

20251104-2025 Q3: The vast majority of newly eligible patients in the U.S. have started on ALYFTREK. Transition patients are switching steadily, and the pace remains steady. Outside the U.S., uptake is strong. ALYFTREK has generated nearly $0.5 billion in revenue in its first 10 months. - [Duncan J. McKechnie](CCO)

Contradiction Point 3

Breakdown of Non-CF Guidance

No specific breakdown provided for the 2026 non-CF revenue guidance.

What is Salveen Richter's (Goldman Sachs) question? - Salveen Richter (Goldman Sachs)

2025Q4: The total revenue guidance of $12.95-$13.1B includes a non-CF contribution of ≥$500M. No further breakdown of CF revenue by product was provided. - [Charles Wagner](COO & CFO)

What factors are included in the 2026 guidance for the CF component (ALYFTREK and TRIKAFTA), and how did ALYFTREK perform in the recent quarter? - Philip Nadeau (TD Cowen)

2025Q3: For CASGEVY, visibility comes from a strong 2025 with >300 patient initiations and the expected patient journey duration. For JOURNAVX, confidence is based on the plan to more than triple prescriptions in 2026 vs. 2025 and improved revenue conversion... - [Charles Wagner](COO & CFO)

Contradiction Point 4

JOURNAVX 2026 Prescription Growth Guidance

Specific guidance on JOURNAVX prescription growth for 2026 is provided in Q4 but was not given in Q3.

What were the key takeaways from the earnings call with Philip Nadeau of TD Cowen? - Philip Nadeau (TD Cowen)

2025Q4: For JOURNAVX, confidence is based on the plan to more than triple prescriptions in 2026 vs. 2025 and improved revenue conversion... - [Charles Wagner](COO & CFO)

What is the breakdown between CASGEVY and JOURNAVX for the $500M+ non-CF guidance, and what supports confidence in this significant year-over-year growth? - Philip Nadeau (TD Cowen)

2025Q3: It is too early to provide 2026 guidance until contracting and payer mix are finalized. - [Charles Wagner](COO & CFO)

Contradiction Point 5

JOURNAVX Gross-to-Net Trajectory

Contradiction on whether gross-to-net will normalize or remain elevated.

What were Barclays Bank PLC's earnings? - Eliana Merle (Barclays Bank PLC)

2025Q4: Gross-to-net dynamics are influenced by multiple factors (prescription length, insurance type, patient support program), not just the channel mix. - [Duncan J. McKechnie](CCO)

How will the JOURNAVX retail vs. hospital prescription mix evolve and affect gross-to-net and treatment duration? - Salveen Jaswal Richter (Goldman Sachs Group, Inc.)

2025Q2: As payer coverage expands, these programs will be retired, and gross-to-net will normalize over the course of the year. - [Charles F. Wagner](CFO)